Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Thrombosis Research

Background:

• Platelet activation and thrombus formation are critical in acute coronary syndromes and restenosis.
• Aspirin and clopidogrel are standard antiplatelet agents, but broader spectrum agents are sought.
• First-generation oral GPIIb/IIIa antagonists showed promise but disappointing clinical trial outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of orbofiban, an oral GPIIb/IIIa antagonist, for antithrombotic protection.
• To assess orbofiban's potential for chronic oral administration in cardiovascular disease management.

Main Methods:

• Preclinical studies in canine models of thrombosis to assess antithrombotic effects.
• Pharmacokinetic evaluation of orbofiban's bioavailability and half-life.
• Clinical trials to assess platelet inhibition and clinical outcomes.

Main Results:

• Orbofiban demonstrated potent and specific inhibition of fibrinogen binding to GPIIb/IIIa, inhibiting platelet aggregation.
• Preclinical studies showed prevention of thrombus formation without major bleeding.
• Orbofiban exhibited favorable bioavailability (28%) and a long half-life (18 hr).
• Clinical trials confirmed orbofiban's pharmacodynamic effect of platelet inhibition but failed to show clinical benefit.

Conclusions:

• Orbofiban effectively inhibits platelet aggregation and thrombus formation in preclinical settings.
• Despite favorable pharmacokinetics and safety profile, orbofiban did not translate to clinical benefit in large-scale trials.
• Further research into GPIIb/IIIa antagonists requires careful consideration of clinical efficacy beyond platelet inhibition.